The use of toxicokinetics for the safety assessment of drugs acting in the brain
- 1 August 1995
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 11 (1-3) , 193-216
- https://doi.org/10.1007/bf02740695
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Are interspecies comparisons in the toxicity of centrally acting drugs valid without brain concentrations? A commentaryNeurochemistry International, 1995
- Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: Relationship with brain concentrations of fluoxetine and norfluoxetineLife Sciences, 1994
- Pharmacokinetics and brain entry of alaptide, a novel nootropic agent, in mice, rats and rabbitsJournal of Pharmacy and Pharmacology, 1991
- Reduction of in vivo binding of [3H]paroxetine in mouse brain by 3,4-methylenedioxymethamphetamineNeuropharmacology, 1990
- Stereochemistry of the metabolism of MDMA to MDALife Sciences, 1989
- The absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitorJournal of Medicinal Chemistry, 1988
- IV. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effectsLife Sciences, 1985
- Inhibition of serotonin uptake by optical isomers of fluoxetineDrug Development Research, 1985
- Integrated Pharmacokinetic-Dynamic Modeling of Drugs Acting on the CNSDrug Metabolism Reviews, 1984
- Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1982